Clinical trial NCT01140737: A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas
Official title: A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Soft Tissue Sarcoma
Keywords: advanced soft tissue sarcoma
Lead sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: University of Birmingham
name: Cancer Research UK
name: Pfizer
First posted: 2010-06-09
Enrollment: 145
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study objective is to evaluate the therapeutic activity, safety and tolerability of axitinib in patients with advanced/metastatic soft tissue sarcoma who are unsuitable for or have relapsed after standard chemotherapy. The therapeutic activity will be separately assessed in angiosarcoma, synovial sarcoma, leiomyosarcomas and other sarcomas.

Detailed description: Soft tissue sarcomas are a heterogeneous group of rare malignancies that account for 0.72% of new malignancies and 0.65% of malignant deaths. Advanced sarcomas carry a poor prognosis. Angiogenesis is a hallmark of tumour growth, and there is increasing evidence that antiangiogenic drugs, including axitinib, can lead to tumour regression and improve patient survival in a variety of tumours.

Patients with angiosarcoma, synovial sarcoma, leiomyosarcoma and other sarcomas will be separately evaluated.

Patients will take axitinib 5mg tablets by mouth twice daily. This will be continued for 2 years or until disease progression, or development of limiting toxicity. In the event of severe toxicity, axitinib will be stopped until the toxicity has improved. Treatment may be interrupted for a maximum of 2 weeks. Following this, axitinib can be restarted at a lower dose of 3 mg twice daily. If the toxicity has not improved sufficiently, axitinib will be permanently stopped.

Patients will be monitored once weekly for the first month, then at 4 week intervals. Toxicity will be closely monitored. At each clinic visit, patients will have a physical examination and a routine blood test. A Chest x-ray, CT and/or MRI scans will be done before study entry, then every 12 weeks and at the end of treatment. Disease evaluation will be carried out 12 weeks after study entry, then every 12 weeks until disease progression. After disease progression, patients will be followed up every 3 months for survival. Patients will be followed up until death or a minimum follow up period of 1 year.

Patients will be enrolled from hospitals all over the UK.

Eligibility criteria: Inclusion Criteria:

* Pathologically confirmed soft tissue sarcoma, including:

  * Angiosarcoma, including intermediate and malignant vascular tumours (WHO classification, 2002) and Kaposi's sarcoma.
  * Leiomyosarcoma, including uterine, skin or non organ origin.
  * Synovial sarcoma.
  * Other eligible subtypes of soft tissue sarcoma of Trojani intermediate or high grade, including fibroblastic, fibrohistiocytic, adipocytic, rhabdomyosarcoma, malignant peripheral nerve sheath, and not otherwise specified. See exclusion criteria for ineligible subtypes.
* Locally advanced or metastatic disease incurable by surgery or radiotherapy.
* Measurable disease according to RECIST criteria.
* Evidence of objective disease progression in the past 6 months, without anticancer treatment since progression.
* Patients ineligible for chemotherapy (eg. through age, clinical condition or patient refusal) or who have received no more than two prior chemotherapy regimens.
* Age \>or = 16.
* WHO performance status 0, 1 or 2.
* At least 4 weeks from prior anticancer treatment (surgery, radiotherapy and systemic therapies) and full recovery from all their adverse effects.
* No evidence of preexisting uncontrolled hypertension as documented by 2 baseline blood pressure readings taken at least 1 hour apart. The baseline systolic blood pressure readings must be \< or = 140 mm Hg, and the baseline diastolic blood pressure readings must be \< or = 90 mm Hg. Patients whose hypertension is controlled by antihypertensive therapies are eligible.
* Adequate physiological function:

  * renal : calculated or measured creatinine clearance \> or = 50 ml/min using the Cockcroft-Gault formula (see appendix 5).
  * haematological: Absolute Neutrophil Count (ANC) \> or = 1.5 x 109/L, platelets \> or = 100 x 109/L, International Normalized Ratio (INR) \< or = 1.2.
  * hepatic: bilirubin within normal range, AST and ALT \< or = 3 x upper limit of normal.
  * cardiac: Left Ventricular Ejection Fraction (LVEF) measured by Echocardiogram or Multi Gated Acquisition Scan (MUGA) within normal range.
  * Urinary protein \<2+ by urine dipstick. If dipstick is \>2+ then a 24-hour urine collection can be done and the patient may enter only if urinary protein is \<2 g per 24 hours.
* Negative pregnancy test and agrees to comply with contraceptive measures
* Able to swallow oral medication.

Exclusion Criteria:

* Ineligible pathological subtypes including:

  * Osteosarcoma
  * Ewings/Primitive Neuroectodermal Tumour (PNET sarcomas)
  * Chondrosarcoma
  * Gastrointestinal stromal tumours (GIST)
  * Dermatofibrosarcoma protuberans (DFSP)
  * Malignant mesothelioma
  * Mixed mesodermal tumours of uterus
  * Known central nervous system metastases.
  * Age \< 16.
  * Current use or anticipated need for treatment with drugs that are known CYP3A4 or CYP1A2 inducers (i.e., carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, primidone, rifabutin, rifampicin, and St. John"s Wort).
* Current use or anticipated need for treatment with drugs that are known potent CYP3A4 inhibitors (i.e., grapefruit juice, verapamil, ketoconazole, miconazole, itraconazole, voriconazole, erythromycin, clarithromycin, ergot derivatives, indinavir, saquinavir, ritonavir, nelfinavir and lopinavir).
* Previous malignancies (except curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix or breast) within the past 3 years.
* Heart failure \> or = New York Heart Association (NYHA) class II.
* History within the previous 6 months of any blood clots in the sputum or streaky haemoptysis that was persistent (\> 2 weeks) or recurrent (\> 3 episodes).
* Patients with cavitating lung metastases or any metastasis abutting or invading a major pulmonary blood vessel on baseline CT or MRI scan.
* History of bleeding diathesis or coagulopathy within 12 months of study entry
* Any of the following within the 12 months prior to trial drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism.
* Therapeutic dose warfarin. Low molecular weight heparin is permitted.
* Regular treatment with antiplatelet medication, including aspirin \>325 mg/day or NSAIDs
* History of malabsorption or major gastrointestinal tract resection likely to affect trial drug absorption.
* Pregnancy or breastfeeding. Female patients must be surgically sterile or be postmenopausal, or must agree to use two effective contraception measures during the period of therapy which should be continued for 4 weeks after the last dose of trial therapy. Male patients must be surgically sterile or must agree to use effective contraception during the period of therapy which should be continued for 4 weeks after the last dose of trial therapy . The definition of effective contraception will be based on the judgment of the Investigator or designee.

Primary outcomes:
measure: Progression-free survival rate at 12 weeks after starting treatment, defined according to the Response Evaluation Criteria In Solid Tumours(RECIST criteria)
timeFrame: 12 weeks after trial entry, the final analysis of the primary outcome measure will take place after all patients have been followed for a minimum of 12 weeks
Secondary outcomes:
measure: Tumour response rate (using RECIST criteria)
timeFrame: 12 weeks and final analysis of all outcome measures will take place after all patients have been followed up for a minimum of 1 year.
measure: Progression-free interval
timeFrame: final analysis of all outcome measures will take place after all patients have been followed up for a minimum of 1 year.
measure: Progression-free survival time
timeFrame: final analysis of all outcome measures will take place after all patients have been followed up for a minimum of 1 year.
measure: Overall survival time
timeFrame: final analysis of all outcome measures will take place after all patients have been followed up for a minimum of 1 year.
measure: Change in performance status
timeFrame: final analysis of all outcome measures will take place after all patients have been followed up for a minimum of 1 year.
measure: Toxicity rate
timeFrame: final analysis of all outcome measures will take place after all patients have been followed up for a minimum of 1 year.
Other outcomes:
Locations:
city: Aberdeen
country: United Kingdom
facility: Aberdeen Royal Infirmary
state: Scotland
city: Edinburgh
country: United Kingdom
facility: Western General Hospital
state: Scotland
city: Bristol
country: United Kingdom
facility: Bristol Haematology & Oncology Centre
city: Leeds
country: United Kingdom
facility: St. James's Hospital
city: London
country: United Kingdom
facility: Royal Marsden Hospital
city: London
country: United Kingdom
facility: Royal Marsden
city: London
country: United Kingdom
facility: University College London Hospitals
city: Manchester
country: United Kingdom
facility: Christies
city: Nottingham
country: United Kingdom
facility: Nottingham City Hospital
city: Oxford
country: United Kingdom
facility: Churchill Hospital
city: Sheffield
country: United Kingdom
facility: Penella Woll
city: Southampton
country: United Kingdom
facility: Southampton General Hospital
city: Wirral
country: United Kingdom
facility: Clatterbridge Centre for Oncology
Study officials:
affiliation: Weston Park Hospital, Sheffield, UK
name: Penella Woll, BMedSci
role: PRINCIPAL_INVESTIGATOR
References: